According to the data published in the National Institutes of Health (NIH) in January 2017, the most common overall cause of female infertility is the failure to ovulate, which occurs in 40% of women with infertility issues, globally. To treat such infertility problems in females, clomiphene citrate is the first choice of medicine for the past 40 years, according to the Global Library of Women’s Medicine. Gynecologists prescribe clomiphene for 1 to 6 months or more with a low dose of 50 mg daily (1 tablet) for 5 days. If ovulation does not occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days is prescribed.
According to a study called ‘Clomiphene citrate usage pattern in India' conducted by Fertility Science and Research in 2014, ovulation rate was reported to increase from 21% to 60% and the pregnancy rate was noticed to be increased by 11% to 30% by majority of participants. The ovulation rate and pregnancy rate was increased using clomiphene citrate because of increased secretion of hypothalamic gonadotropin-releasing hormone (GnRH) to increase the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which will, in turn, stimulate ovarian follicular activity.
Market Dynamics
High incidence of polycystic ovarian syndrome is expected to be a key driver for the clomiphene citrate market growth. For instance, according to an article published in 2014 in Clinical Epidemiology, polycystic ovarian syndrome affects 8% to 20% of the reproductive-age women, globally. According to the World Health Organization, in 2012, polycystic ovarian syndrome affected 116 million women, worldwide.
The clomiphene citrate market growth is hindered by side effects shown by this drug, which includes headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus congestion, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, abnormal bleeding or spotting, vomiting, injection site pain, redness, dizziness, and ovarian hyper-stimulation syndrome (OHSS). For instance, according to a study published in NCBI, in 2016, 10% to 20% of women who consumed clomiphene citrate developed a mild form of OHSS, which will usually resolve on its own. Severe cases of OHSS occurred in less than one percent of patients in the U.S.
Key features of the study:
- This report provides in-depth analysis of the global clomiphene citrate market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global clomiphene citrate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Sanofi S.A., Par Pharmaceutical, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., and Shanghai Trifecta Pharma Co. Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global clomiphene citrate market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for clomiphene citrate market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Clomiphene Citrate Market, By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- Global Clomiphene Citrate Market, By Distribution Channel::
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Clomiphene Citrate Market, By Region:
- North America
- By Country:
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Indication:
- PCOS
- Secondary Amenorrhea
- Psychogenic Amenorrhea
- Amenorrhea Galactorrhea Syndrome
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Sanofi S.A.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Par Pharmaceutical
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Unichem Laboratories Ltd.
- Emcure Pharmaceuticals Ltd.
- Serum Institute of India Pvt. Ltd.
- Incepta Pharmaceuticals Ltd.
- Shanghai Trifecta Pharma Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
